Navigation Links
Ranbaxy to Market Desvenlafaxine Base Extended Release Tablets in the U.S.
Date:3/5/2013

PRINCETON, N.J., March 5, 2013 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that it has entered into an in-licensing agreement with Alembic Pharmaceuticals Limited to exclusively market Desvenlafaxine Base Extended Release Tablets in the U.S. healthcare system.  Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the New Drug Application (NDA) Desvenlafaxine Base Extended Release Tablets.  The product is a bioequivalent version of innovator drug, Pristiq® by Pfizer, Inc.*  The market size for Pristiq® is U.S. $ 590 Mn (IMS – MAT January 2013).

Desvenlafaxine Base Extended Release Tablets is indicated for the treatment of major depressive disorder. The product will be available in 50 mg and 100 mg dosage strengths. Alembic has received the final approval from the U.S. Food and Drug Administration (USFDA) and Ranbaxy expects the product to be available in the U.S. marketplace during the first quarter of 2013.

Commenting on the development, Bill Winter , Vice President, Ranbaxy Trade Sales and Distribution, North America said, "Ranbaxy is pleased to partner with Alembic to offer a safe, effective, affordable generic alternative to the brand formulation much ahead of the patent expiration.  We are committed to expand our portfolio of products offered in the U.S. market for the benefit of patients, prescribers and the U.S. healthcare system."

About Ranbaxy Pharmaceuticals Inc.
Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited, India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.

<
'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA
2. Ranbaxy Commends New IMS Study Which Credits Generic Prescription Drugs With $1 Trillion Savings In U.S. Health Care Costs Over Past 10 Years
3. Ranbaxy Launches Authorized Generic Of Pioglitazone In The U.S.
4. Ranbaxy Issues Voluntary Nationwide Recall of 41 lots of Atorvastatin Calcium Tablets 10 mg, 20 mg and 40 mg Due to Potential Presence of Foreign Substance
5. Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler
6. ulrich medical USA™ Releases New Expandable Spinal Implant for US Market
7. Nektar to Announce Financial Results for the First Quarter of 2012 on Wednesday, May 2, 2012, After Close of U.S.-Based Financial Markets
8. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
9. International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets.
10. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
11. Ophthalmic Drugs: World Market Prospects 2012-2022
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) today announced ... of 2013 on Monday, February 3, 2014. A press release ... of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) ... operating highlights and financial results for the fourth quarter and ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... BERNARDINO, Calif., Jan. 25, 2011 Most people know ... know why they should take them or which vitamins ... are getting the vitamins they need, the Stater Bros. ... free 5-minute personal health survey.  The recommendations from this ...
... Jan. 25, 2011 Reportlinker.com announces that a ... catalogue: Emerging Regional Markets for ... The overall emerging markets for ... regions include Latin America, China, Eastern Europe, the ...
Cached Medicine Technology:Stater Bros. Introduces Free Personal Vitamin Recommendation Program 2Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 2Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 3Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 4Reportlinker Adds Emerging Regional Markets for Therapeutic Drugs 5
(Date:7/9/2014)... -- Vasectomy was associated with a small increased risk ... or lethal prostate cancer according to a new study ... found that the association remained even among men who ... lethal cancer cannot be explained by diagnostic bias. It ... to look at the link between vasectomy and prostate ...
(Date:7/9/2014)... Studying the most common type of lung cancer, researchers ... a role in forming tumors. The new knowledge may ... these genetic changes already are available or are in ... , investigators from The Cancer Genome Atlas (TCGA), including ... Louis, Harvard Medical School and other institutions, studied tumors ...
(Date:7/9/2014)... The Miriam Hospital have found that people with ... depressed have difficulty sticking to a pulmonary rehabilitation ... women, and screening and brief treatment of depression ... study and its findings are published in print ... obstructive pulmonary disease is a common and often ...
(Date:7/9/2014)... KNOXVILLEAmphibian declines and extinctions around the world have ... chytridiomycosis, but new research from the National Institute ... another pathogen, ranavirus, may also contribute. , ... that ranavirus, which causes severe hemorrhage of internal ... populations of wood frogs if they are exposed ...
(Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
Breaking Medicine News(10 mins):Health News:Vasectomy may increase risk of aggressive prostate cancer 2Health News:Lung cancer study hints at new treatments 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... By Amanda Gardner HealthDay Reporter , TUESDAY, ... during their younger years, especially women, are less likely ... types struggle with, researchers say. But regular exercise ... if it reached about 150 minutes of moderate to ...
... vaccines targeted against various types of cancer has raised ... however, is that these promising treatments are difficult to ... cellular target to stop cancer growth without inactivating the ... report a laboratory finding that has the potential to ...
... UT Southwestern Medical Center have discovered sets of genes ... survival time and potential new treatments for patients with ... treatment vary widely and often depend on subtle biological ... pharmacology at UT Southwestern and co-lead author of the ...
... The latest weapon against inoperable liver cancer is so ... but according to interventional radiologists at the Indiana University ... therapeutic punch. The glass spheres contain a radioactive ... radiation for a very limited distance so that healthy ...
... HealthDay Reporter , TUESDAY, Dec. 14 (HealthDay News) ... key component of the new U.S. health-care reform law -- ... first successful challenge to the controversial legislation. ... Barack Obama and fellow Democrats against Republicans, will continue to ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Scientists report ... associated with adrenal gland tumors by identifying 13 new ... adrenal gland, which is located above the kidney. These ... be cancerous -- cause the adrenal gland to produce ...
Cached Medicine News:Health News:Regular Exercise While Young May Slow Middle-Age Spread 2Health News:Regular Exercise While Young May Slow Middle-Age Spread 3Health News:UNC scientists discover potential strategy to improve cancer vaccines 2Health News:Gene information predicts survival time, possible new treatment options for lung-cancer patients 2Health News:Y-90 radioembolization offers promise for late-stage liver cancer 2Health News:Health-Care Reform Faces Long Legal Fight 2Health News:Health-Care Reform Faces Long Legal Fight 3Health News:Health-Care Reform Faces Long Legal Fight 4
... three strongest enzymes available for maximum cleaning ... blood, tissue, mucous, and other organic matter ... in hard to reach places like box ... reduces the need for scrubbing and prolongs ...
... MPD is the highly concentrated ... instruments manually or with an ultrasonic ... to remove blood and organic material ... Use MPD to clean surgical instruments ...
... The Shandon Cytospin has ... over 35 years. More than ... simple, reliable instrument. It provides ... liquid matrix, especially hypocellular fluids ...
The ISI Digi Grip has the strength needed for secure ,upper extremity traction....
Medicine Products: